Loading
LH
Lucira Health, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Engelson Erik T., was filed 19 Sept 2022.
Lucira Health, Inc.: what insiders have been doing
Lucira Health, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Lucira Health, Inc. in twelve months, the latest record being from 13 March 2023.
Looking back to 2021, when coverage begins, insiders filed 4 purchases and 35 sales.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
83
Thresholds
n/a
Buy Volume
€49M
4 ops. · all time
Sell Volume
€990,848
35 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$80.1M
Gross profitUS$8.8M11% margin
Net income-US$55.8M-69.7% margin
Last declaration on 13 March 2023
Declarations83 total
574,666 shares@ US$1.0346.6% of flowCommon StockSEC:0001209191-23-018261:1
60,000 shares@ US$1.095.2% of flowCommon StockSEC:0001209191-23-018261:2
81,717 shares@ US$0.4823.3% of flowCommon StockSEC:0001209191-23-018223:1
9,675 shares@ US$1.0734.5% of flowCommon StockSEC:0001209191-23-018225:1
4,742 shares@ US$1.0015.8% of flowCommon StockSEC:0001209191-23-018225:2
1,910 shares@ US$0.573.6% of flowCommon StockSEC:0001209191-23-018225:3
2,382 shares@ US$0.453.5% of flowCommon StockSEC:0001209191-23-018225:4
30,102 shares@ US$1.1527.1% of flowCommon StockSEC:0001209191-23-018223:0
10,674 shares@ US$1.1495.5% of flowCommon StockSEC:0001209191-23-018225:0
8,405 shares@ US$1.0023.7% of flowCommon StockSEC:0001209191-23-018219:0
574,666 shares@ US$0.8277.0% of flowCommon StockSEC:0001209191-23-018261:0
5,028 shares@ US$0.271.1% of flowCommon StockSEC:0001209191-23-011047:0
4,263 shares@ US$0.161.9% of flowCommon StockSEC:0001209191-22-062409:0
3,754,084 sharesCommon StockSEC:0001667731-22-000447:1
5,173,026 sharesCommon StockSEC:0001667731-22-000447:2
735,475 sharesCommon StockSEC:0001667731-22-000447:3
256,742 sharesCommon StockSEC:0001667731-22-000447:4
725,675 sharesCommon StockSEC:0001667731-22-000447:5
3,461,764 sharesCommon StockSEC:0001667731-22-000447:0
31,000 shares@ US$0.3322.8% of flowCommon StockSEC:0001209191-22-060495:1
25,236 shares@ US$0.377.0% of flowCommon StockSEC:0001209191-22-060480:1
3,429 shares@ US$0.333.3% of flowCommon StockSEC:0001209191-22-060495:0
8,011 shares@ US$0.382.6% of flowCommon StockSEC:0001209191-22-060480:0
7,537 shares@ US$0.422.7% of flowCommon StockSEC:0001209191-22-060487:0
1,583 shares@ US$0.364.5% of flowCommon StockSEC:0001209191-22-059999:0
25 of 83 declarations
About Lucira Health, Inc.
Lucira Health, Inc. was a U.S.-based medical technology company listed on the NASDAQ under ticker LHDX in the United States. Founded in 2013 under the name DiAssess Inc. and later renamed Lucira Health, the company was headquartered in Emeryville, California. Its business model centered on developing, manufacturing, and commercializing infectious-disease diagnostic tests designed for at-home use, with a value proposition built around speed, ease of use, and decentralized testing outside traditional laboratories. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000156459021017123/lhdx-10k_20201231.htm?utm_source=openai))
Lucira’s flagship product was its at-home COVID-19 test, which became one of the early rapid molecular self-tests authorized in the United States. That product gave the company meaningful visibility during the pandemic-driven surge in decentralized diagnostics. Over time, Lucira also presented itself as a broader respiratory-testing platform company, with SEC filings and investor communications referring to tests for influenza and other infectious diseases as part of its product and development strategy. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000119312522072139/d325713dex991.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Lucira operated in a crowded in vitro diagnostics market dominated by much larger players with deeper commercial infrastructure, broader regulatory reach, and stronger balance sheets. Its differentiation came from combining molecular testing, home use, and fast turnaround times. However, that niche depended heavily on the post-pandemic trajectory of consumer demand and on Lucira’s ability to expand beyond a single COVID-led revenue driver. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000119312522072139/d325713dex991.htm?utm_source=openai))
Geographically, Lucira’s operational footprint was primarily U.S.-centric, anchored in California and accessed through the NASDAQ market in the United States. The company also referenced international expansion plans in its SEC materials and highlighted manufacturing and commercialization partnerships as part of its scale-up efforts. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000156459021017123/lhdx-10k_20201231.htm?utm_source=openai))
The most important recent development was the company’s financial deterioration and its Chapter 11 filing in February 2023. Following that restructuring process, Lucira’s assets were sold to Pfizer, fundamentally changing the investment case for the original standalone issuer. For investors, Lucira is best understood as a pandemic-era diagnostics growth story that later faced a sharp reset as COVID testing demand normalized and the company’s strategic options narrowed. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000119312523044968/d642141dex991.htm?utm_source=openai))
